TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21997224

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 166

Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 166
Study: 20186887

Group type: EXPERIMENTAL
Intervention: High PSWT (PD 200 μsec, PRR 800 Hz, MP 24 W, 10 minutes)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low PSWT (PD 100 μsec, PRR 200 Hz, MP 3 W, 10 minutes)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo PSWT (PD 20 μsec, PRR 50 Hz, MP 0.05 W, 10 minutes)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control condition (no treatment, 10 minutes)
Number of subjects: 31
Study: 18317973

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 3212

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 3212
Study: 15977265

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 410
Study: 14624186

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 131
Study: 10774806

Group type: EXPERIMENTAL
Intervention: HIV-1 Immunogen (REMUNE)
Number of subjects: 0
Study: 8858279

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg with grapefruit juice (GraMid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 10 mg with water (Mid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg with grapefruit juice (GraTrz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg with erythromycin (EryMid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grapefruit juice (Gra)
Number of subjects: 0
Study: 1454971

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4061978

Group type: EXPERIMENTAL
Intervention: Fenoterol (320 micrograms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31547736

Group type: EXPERIMENTAL
Intervention: CPX-351 (vyxeos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7+3 regimen (cytarabine and anthracycline)
Number of subjects: 0
Study: 28816693

Group type: EXPERIMENTAL
Intervention: Multiple-frequency matching therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-frequency matching therapy
Number of subjects: 0
Study: 26908630

Group type: EXPERIMENTAL
Intervention: 0.1% rh-FGF-2/β-TCP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 0.3% rh-FGF-2/β-TCP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 0.4% rh-FGF-2/β-TCP
Number of subjects: 88

Group type: COMPARATOR
Intervention: β-TCP alone (control)
Number of subjects: 88
Study: 24257717

Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg/day
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study: 22100462

Group type: EXPERIMENTAL
Intervention: Traditional-bridge progression
Number of subjects: 51

Group type: COMPARATOR
Intervention: Suspension-exercise-bridge progression
Number of subjects: 51
Study: 19615160

Group type: EXPERIMENTAL
Intervention: Traditional serrated adenoma (TSA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional adenoma
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Serrated carcinoma
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non‐serrated adenocarcinoma (N‐Sca)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Villous adenoma (AD)
Number of subjects: 75
Study: 17307663

Group type: EXPERIMENTAL
Intervention: CART with bootstrap aggregation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Expert evaluation
Number of subjects: 144
Study: 16138217

Group type: EXPERIMENTAL
Intervention: Purple grape juice (GJ), 500 ml/day for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Red wine (RW), 250 ml/day for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (24 normal subjects)
Number of subjects: 16
Study: 12045521

Group type: EXPERIMENTAL
Intervention: Surgical candidates with chronic low back pain
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control subjects with back pain
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control subjects free of back pain
Number of subjects: 294
Study: 12017006

Group type: EXPERIMENTAL
Intervention: Sustained release formulation of isosorbide-5-mononitrate (40 mg, qd)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional preparation of isosorbide-5-mononitrate (20 mg, bid)
Number of subjects: 10
Study: 8615057

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2378185

Group type: EXPERIMENTAL
Intervention: 500 micrograms PGE2 gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study: 348558

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30076254

Group type: EXPERIMENTAL
Intervention: Access to web-based patient information
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard care (no access to web-based information)
Number of subjects: 148
Study: 28080250

Group type: EXPERIMENTAL
Intervention: Daclizumab 150 mg subcutaneous
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular interferon beta-1a 30 µg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 0
Study: 26200977

Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation plus regional nodal irradiation (nodal-irradiation group)
Number of subjects: 1832

Group type: COMPARATOR
Intervention: Whole-breast irradiation alone (control group)
Number of subjects: 1832
Study: 24438351

Group type: EXPERIMENTAL
Intervention: Counselling alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint counselling and financial support
Number of subjects: 0

Group type: COMPARATOR
Intervention: No support
Number of subjects: 0
Study: 23026182

Group type: EXPERIMENTAL
Intervention: Ragweed sublingual allergy immunotherapy tablet (AIT) at doses of 3, 6, 12, 24, 50, or 100 Amb a 1-U, administered once daily for 28 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ragweed sublingual allergy immunotherapy tablet (AIT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19528135

Group type: COMPARATOR
Intervention: Methadone Maintenance Treatment (MMT) alone
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Injectable opioids (diacetylmorphine or hydromorphone) plus adjunctive MMT if deemed appropriate
Number of subjects: 253
Study: 17328961

Group type: EXPERIMENTAL
Intervention: Intensive group cognitive therapy (IGCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Psychotherapy (general)
Number of subjects: 100
Study: 15229304

Group type: EXPERIMENTAL
Intervention: Multivitamins (vitamins B, C, and E)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Vitamin A alone
Number of subjects: 1078
Study: 11249054

Group type: EXPERIMENTAL
Intervention: Epirubicin-based chemotherapy
Number of subjects: 585
Study: 9722129

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/day) plus ipriflavone (600 mg/day)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/day)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: ipriflavone (600 mg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study: 8202971

Group type: EXPERIMENTAL
Intervention: Ganglioside GM1 100 mg intramuscularly daily for 28 days
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Ganglioside GM1
Number of subjects: 287

Group type: COMPARATOR
Intervention: Ganglioside GM1 and Placebo
Number of subjects: 287
Study: 2562020

Group type: EXPERIMENTAL
Intervention: Hydroxylapatite (HA) - Interpore 200 implanted into periodontal defects
Number of subjects: 99

Group type: COMPARATOR
Intervention: Open flap curettage
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Histological evaluation of HA implants
Number of subjects: 99
Study: 433813

Group type: EXPERIMENTAL
Intervention: Dealcoholized Zinfandel wine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ethanol (9.3% w/v aqueous alcohol solution)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Zinfandel wine (9.3% w/v alcohol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 6
Study: 31144977

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation 30 mg•kg‐1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation
Number of subjects: 11
Study: 27647261

Group type: EXPERIMENTAL
Intervention: Tailored patient-activation letter communicating BMD test results plus an educational brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 7749
Study: 26115073

Group type: EXPERIMENTAL
Intervention: Multimodal supervised exercise (group exercise classes twice a week for 12 months and once a week for the subsequent 12 months and home exercises)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Multimodal supervised exercise
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control (maintained current physical activity)
Number of subjects: 409
Study: 23348607

Group type: EXPERIMENTAL
Intervention: Tofacitinib at 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib at 10 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21113620

Group type: EXPERIMENTAL
Intervention: Capecitabine and celecoxib
Number of subjects: 110

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 110

Group type: COMPARATOR
Intervention: XELOX (capecitabine plus oxaliplatine)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: XELOX + celecoxib
Number of subjects: 110
Study: 18403219

Group type: EXPERIMENTAL
Intervention: FREMS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17653881

Group type: EXPERIMENTAL
Intervention: 20,000 U rhEPO
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40,000 U rhEPO
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous iron alone
Number of subjects: 60
Study: 14998402

Group type: EXPERIMENTAL
Intervention: 1000 mg day(-1) terbinafine
Number of subjects: 63

Group type: COMPARATOR
Intervention: 500 mg day(-1) terbinafine
Number of subjects: 63
Study: 11320011

Group type: EXPERIMENTAL
Intervention: Verteporfin (6 mg per square meter of body surface area; n = 81)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water; n = 39)
Number of subjects: 120
Study: 9083900

Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclosan/zinc citrate toothpaste
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 8446045

Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp (HY)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous glucose administration (IV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test (IVGTT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Basal proinsulin concentrations
Number of subjects: 17

Group type: COMPARATOR
Intervention: Basal molar proinsulin:insulin ratio (P:I)
Number of subjects: 17
Study: 3513687

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.025% topical ophthalmic solution
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 39
Study: 11401762

Group type: EXPERIMENTAL
Intervention: LAN exposure
Number of subjects: 53

Group type: COMPARATOR
Intervention: EMF exposure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Women with high or low melatonin secretion
Number of subjects: 53
Study: 30497789

Group type: EXPERIMENTAL
Intervention: Aspirin and low molecular weight dextran (Group A)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Group B)
Number of subjects: 454

Group type: COMPARATOR
Intervention: No antithrombotic agent (Group C)
Number of subjects: 454
Study: 30012180

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 sessions; 5 consecutive weekdays/wk, 2 mA, 20 minutes) + hypocaloric diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS + hypocaloric diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active tDCS + hypocaloric diet
Number of subjects: 0
Study: 26678652

Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided neck-specific exercise with a behavioural approach (NSEB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided neck-specific exercise (NSE)
Number of subjects: 140

Group type: COMPARATOR
Intervention: General physical activity (PPA)
Number of subjects: 140
Study: 24690267

Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative (QIC) based on the Breakthrough Series (BTS) model
Number of subjects: 6592

Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 6592
Study: 22354243

Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion (2 units of erythrocytes transfused 1 to 2 days before surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (transfusions as indicated)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion
Number of subjects: 60
Study: 20385630

Group type: EXPERIMENTAL
Intervention: Educational-book group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Noneducational-book group
Number of subjects: 168

Group type: COMPARATOR
Intervention: No-book group
Number of subjects: 168
Study: 17481946

Group type: EXPERIMENTAL
Intervention: Tolvaptan in patients with acute decompensated HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nesiritide in patients with chronic decompensated HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure reduction in hypertensive patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone in mild to moderate chronic HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging for selecting HF patients for revascularisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crataegus extract added to standard HF therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI in patients without HF or major cardiac dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HF nurse-intervention in the COACH study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HF nurse-intervention in the REMADHE study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNP for distinguishing cardiac and pulmonary breathlessness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary intervention in post-MI patients (THIS-diet study)
Number of subjects: 0
Study: 15592070

Group type: EXPERIMENTAL
Intervention: Webcam trainer
Number of subjects: 42

Group type: COMPARATOR
Intervention: Video trainer
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mirror trainer
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All trainers (Webcam, Video, Mirror)
Number of subjects: 42
Study: 12150178

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain, twice daily for 5 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246
Number of subjects: 69
Study: 10453431

Group type: EXPERIMENTAL
Intervention: Coached exercise training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Monitored exercise training
Number of subjects: 49
Study: 7607715

Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg/d
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg/d
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Trandolapril (various doses)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Trandolaprilat
Number of subjects: 298
Study: 1971861

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 654412

Group type: EXPERIMENTAL
Intervention: Oxyfedrine and interval-training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Interval-training alone (placebo group)
Number of subjects: 23
Study: 31084516

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (340 mg/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PL) supplementation (<2.5 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PL) supplementation
Number of subjects: 11
Study: 28424261

Group type: EXPERIMENTAL
Intervention: Full-fat ultra-high temperature (UHT) milk (HTM)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Unprocessed (raw) milk (UM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Water
Number of subjects: 37

Group type: COMPARATOR
Intervention: Full-fat UHT milk diluted 1:1 with water (MW)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Full-fat UHT milk with high-phytate rice (RM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Water with high-phytate rice (RW)
Number of subjects: 37
Study: 25885544

Group type: EXPERIMENTAL
Intervention: Standard TSST-M condition
Number of subjects: 163

Group type: COMPARATOR
Intervention: Low-stress TSST-M condition
Number of subjects: 163
Study: 24236622

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study: 21465243

Group type: EXPERIMENTAL
Intervention: Sertraline for an average of 24 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19733706

Group type: EXPERIMENTAL
Intervention: Newly initiated statin therapy (36 patients)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Long-term statin therapy (38 patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Newly initiated statin therapy
Number of subjects: 74
Study: 17762662

Group type: EXPERIMENTAL
Intervention: Irbesartan for 48 weeks
Number of subjects: 191

Group type: COMPARATOR
Intervention: Atenolol for 48 weeks
Number of subjects: 191

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 191
Study: 15243930

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 1666
Study: 11739431

Group type: EXPERIMENTAL
Intervention: 1 IU/kg BW.wk hGH
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.5 IU hGH (for GH deficient group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: hGH treatment
Number of subjects: 35
Study: 9406880

Group type: EXPERIMENTAL
Intervention: Simple declarative sentences
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subordinate clauses
Number of subjects: 12
Study: 8501178

Group type: EXPERIMENTAL
Intervention: HMG-GRF (500 micrograms twice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: HMG-placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HMG-GRF
Number of subjects: 13
Study: 3306509

Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 plus melphalan 0.4 mg/kg every four weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Melphalan 1 mg/kg every four weeks
Number of subjects: 168
Study: 29539616

Group type: EXPERIMENTAL
Intervention: Resveratrol (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Budesonide (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (2 sprays in each nostril 3 times/day for 1 month)
Number of subjects: 151
Study: 28317297

Group type: EXPERIMENTAL
Intervention: 6-month exercise training
Number of subjects: 248
Study: 25729212

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (8 sessions, 60 minutes each, individual 30 min, group 30 min)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study: 23331722

Group type: EXPERIMENTAL
Intervention: Intervention-2 group (diabetes specific 30 minutes counseling session)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Intervention-1 group (standard cessation advice)
Number of subjects: 224
Study: 20931299

Group type: EXPERIMENTAL
Intervention: CT + HV (cisplatin + hydralazine + valproate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CT + PLA (cisplatin + placebo)
Number of subjects: 36
Study: 18086516

Group type: EXPERIMENTAL
Intervention: Pain self‐management training group (SMG)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Education-only control condition (BOOK)
Number of subjects: 256
Study: 17038905

Group type: EXPERIMENTAL
Intervention: Immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 40% cyclosporine reduction (group A, 14 patients)
Number of subjects: 42
Study: 12773137

Group type: EXPERIMENTAL
Intervention: PEG-OB (80 mg weekly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PEG-OB
Number of subjects: 24
Study: 10574137

Group type: EXPERIMENTAL
Intervention: 240 mg glycyrrhizin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 160 mg glycyrrhizin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 80 mg glycyrrhizin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (0 mg glycyrrhizin)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All glycyrrhizin groups
Number of subjects: 57